FDA Determines Regulatory Review Period for GALLIPRANT Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for GALLIPRANT, a medication subject to patent extension, following a submission to the U.S. Patent and Trademark Office (USPTO).